1-methyl-6-chromenone indole-2-formamide compound as well as preparation method and application thereof

By developing 1-methyl-6-chromenone indole-2-formamide compounds, inhibiting STAT3 and activating AMPK, the problems of low response rate and drug resistance of existing anti-cancer drugs have been solved, and a variety of factors have been significantly inhibited. Cancer cells proliferate, providing new treatment options for anti-cancer and metabolic diseases.

CN119080755AActive Publication Date: 2024-12-06HENAN RADIOMEDICAL SCI & TECH CO LTD +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410920048.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-12-06
Estimated Expiration
2044-07-10

AI Technical Summary

Technical Problem

The current anti-cancer drugs have low response rates and are prone to resistance, leading to a lack of effective therapeutic drugs, especially when facing a variety of types of cancer and metabolic diseases, especially breast cancer, liver cancer, pancreatic cancer, gastric cancer, etc., to treat Not effective.

Method used

Develop a completely new structure of 1-methyl-6-chromenone indole-2-formamide compound, which significantly inhibits the proliferation of a variety of cancer cells by inhibiting the phosphorylation of STAT3 protein and activates AMPK phosphorylation, and is used for Prepare anti-tumor and metabolic disease drugs.

Benefits of technology

This compound effectively inhibits the proliferation of a variety of cancer cells at extremely low doses, significantly downregulates the activation status of STAT3 and AMPK, has potential anti-cancer and metabolic diseases treatment effects, and provides a new direction for drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The invention discloses a 1-methyl-6-chromenone indole-2-formamide compound as well as a preparation method and application thereof, and the 1-methyl-6-chromenone indole-2-formamide compound contains a 1-methyl-6-chromenone indole-2-formamide parent nucleus group with biological activity and is further chemically modified to generate a plurality of compounds with higher biological activity. The wide application of the compound in biological medicines and the development prospect of medicinal preparations are expanded. The compound can significantly inhibit proliferation of breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, diffuse large B-cell lymphoma and other cells at a low dosage (nanomole), and can effectively inhibit STAT3 protein phosphorylation, which shows that the compound has a prospect of being developed into antitumor drugs. In addition, the compound can also activate AMPK phosphorylation, which indicates that the compound also has huge potential for treating metabolic diseases such as obesity, non-alcoholic fatty liver disease, diabetes mellitus and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of clinical treatment of indications such as tumor targeted therapy and metabolic disease-related diabetes and obesity, and specifically relates to a 1-methyl-6-chromenone indole-2-carboxamide compound, a preparation method and application thereof. Background Art

[0002] Cancer has become an important cause of premature death and shortened life span of the global population. In 2020, there were about 19.3 million confirmed cancer cases worldwide, and nearly 10 million people died of cancer. Experts predict that by 2035, the number of cancer patients worldwide will increase by half. China's cancer incidence and mortality rates account for a high proportion of the world. In 2022, there were about 482,000 new cancer cases and about 321,000 cancer deaths in my country, which are twice and five times that of the United States, respectively. Breast cancer has replaced lung cancer as the world's number one cancer. There are as many as 2.26 million new cases of breast cancer worldwide. In 2020, about 905,700 people were diagnosed with liver cancer worldwide, of which about 830,200 died. It is estimated that by 2040, the number of confirmed cases and deaths of primary liver cancer may increase by more than 55%. In addition, the incidence of gastric cancer and pancreatic cancer is also high, and the prognosis is still poor. Although there have been great advances in the treatment of cancer in clinical practice, due to the heterogeneity and continuous evolution of tumors, the response rate of most drugs is low and they are prone to drug resistance, resulting in a lack of effective therapeutic drugs. Conventional cytotoxic chemotherapy drugs such as paclitaxel, cisplatin, carboplatin and capecitabine have the advantages of a broad anti-cancer spectrum and good efficacy, but they have large toxic side effects and are prone to early drug resistance. Therefore, actively exploring and developing new anti-cancer drugs is of great clinical significance.

[0003] AMP-activated protein kinase (AMPK) is a key regulator of cellular metabolism and plays an important role in diabetes, cancer, and vascular diseases. Therapies targeting AMPK have been widely used in the treatment of various metabolic disorders, including diabetes.

[0004] The present application synthesizes a class of 1-methyl-6-chromenone indole-2-carboxamide compounds with a new structural formula. Through some biological technical analysis, it is found that this class of compounds can significantly inhibit the proliferation of breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, diffuse large B-cell lymphoma and other cells at extremely low doses, and can effectively inhibit STAT3 protein phosphorylation and activate AMPK protein phosphorylation. Therefore, further development of this class of compounds will be of great significance in the application of tumor and metabolic disease treatment. Summary of the invention

[0005] The purpose of the present invention is to provide a 1-methyl-6-chromenone indole-2-carboxamide compound, a preparation method and application thereof.

[0006] A 1-methyl-6-chromenone indole-2-carboxamide compound, the structural formula of which is shown in general formula I:

[0007]

[0008] Among them, R 1 , R 2 Selected from H, -OH, -NH 2 、-NO 2 、-OCH 3 、F、Cl、Br、

[0009] The above-mentioned 1-methyl-6-chromenoindole-2-carboxamide compound is specifically a compound with the following structure:

[0010]

[0011]

[0012]

[0013] A biologically acceptable salt formed by the above-mentioned 1-methyl-6-chromenone indole-2-carboxamide compound and at least one of acetic acid, dihydrofolic acid, benzoic acid, citric acid, sorbic acid, propionic acid, oxalic acid, fumaric acid, maleic acid, hydrochloric acid, malic acid, phosphoric acid, diphosphoric acid, hydrobromic acid, nitric acid, sulfurous acid, sulfuric acid, vanillic acid, tartaric acid, succinic acid, ascorbic acid, boric acid, lactic acid, p-toluenesulfonic acid, salicylic acid and ethylenediaminetetraacetic acid.

[0014] The preparation method of the above-mentioned 1-methyl-6-chromenone indole-2-carboxamide compounds, the synthetic route is as follows:

[0015] The specific synthesis steps are as follows:

[0016] (1) Compound 1, Compound 2, HBTU and DIEA were dissolved in DMF, and after the reaction was completed by stirring at 20-30° C., the reaction solution was diluted with ethyl acetate and washed with saturated brine. The organic phase was spin-dried, slurried with ethyl acetate, and filtered to obtain Compound 3;

[0017] (2) Compound 3, compound 4, Pd(dppf)Cl 2 and potassium acetate were dissolved in DMF, stirred at 90-120°C until the reaction was complete, the reaction solution was diluted with ethyl acetate, washed with saturated brine, the organic phase was dried by spin drying, and column chromatography was performed to obtain compound 5;

[0018] (3) Compound 5, Compound 6, Pd(dppf)Cl 2 and sodium carbonate are dissolved in DMSO, stirred at 90-120° C. until the reaction is complete, the reaction solution is diluted with ethyl acetate and washed with saturated brine, the organic phase is spin-dried and subjected to column chromatography to obtain the compound of formula I.

[0019] Further, in step (1), the molar ratio of compound 1, compound 2, HBTU and DIEA is 1:1:

[0020] (1~1.5):3; In step (2), compound 3, compound 4, potassium acetate and Pd(dppf)Cl 2 The molar ratio is 1:2:3:0.05; in step (3), compound 5, compound 6, sodium carbonate and Pd(dppf)Cl 2 The molar ratio is 1:(1~1.5):

[0021] (1~1.5):0.05.

[0022] Use of the above-mentioned 1-methyl-6-chromenoindole-2-carboxamide compounds or biologically acceptable salts thereof in the preparation of STAT3 protein phosphorylation inhibitors.

[0023] The use of the above-mentioned 1-methyl-6-chromenoindole-2-carboxamide compounds or their biologically acceptable salts in the preparation of anti-tumor drugs, wherein the anti-tumor drugs refer to drugs for treating breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, diffuse large B-cell lymphoma, etc.

[0024] Use of the above-mentioned 1-methyl-6-chromenoindole-2-carboxamide compounds or biologically acceptable salts thereof in the preparation of drugs for activating AMPK.

[0025] The use of the above-mentioned 1-methyl-6-chromenone indole-2-carboxamide compounds or their biologically acceptable salts in the preparation of metabolic drugs. The drugs are drugs for treating metabolic diseases such as obesity, non-alcoholic fatty liver disease, diabetes, etc.

[0026] Specifically, the present invention synthesizes a class of 1-methyl-6-chromenone indole-2-carboxamide compounds RD24V1001, RD24V1002, RD24V1003, RD24V1004, RD24V1005, RD24V1006, RD24V1007, RD24V1008, RD24V1009, RD24V1010, RD24V1011, RD24V1012, RD24V1013, RD24V1014, RD24V1015, RD24V1016, RD24V1017, RD24V1018, RD24V1019, RD24V1020, RD24V1021, RD24 V1022, RD24V1023, RD24V1024, RD24V2001, RD24V2002, RD24V2003, RD24V2004, RD24V2005, RD24V2006, RD24V2007, RD24V2008, RD24V2009, RD24V2010, RD 24V2011, RD24V2012, RD24V2013, RD24V2014, RD24V2015, RD24V2016, RD24V2 017, RD24V2018, RD24V2019, RD24V2020, RD24V2021, RD24V2022, RD24V2023, etc. The CCK-8 method was used to detect the proliferation inhibitory effect of this type of compound on various cancer cells; it can effectively inhibit STAT3 protein phosphorylation and activate AMPK phosphorylation.

[0027] The results show that the compounds of the present invention RD24V1001, RD24V1002, RD24V1003, RD24V1004, RD24V1005, RD24V1006, RD24V1007, RD24V1008, RD24V1009, RD24V1010, RD24V1011, RD24V1012, RD24V1013, RD24V1014, RD24V1015, RD24V1016, RD24V1017, RD24V1018, RD24V1019, RD24V1020, RD24V1021, RD24V1022, RD24V1023, RD24V1024, RD24V1025 2002, RD24V2003, RD24V2004, RD24V2005, RD24V2006, RD24V2007, RD24V2008, RD24V2009, RD24V2010, RD24V2011, RD24V2012, RD24V2013, RD24V2014, RD24V2015, RD24V2016, RD24V2017, RD24V2018, RD24V2019, RD24V2020, RD24V2021, RD24V2022, and RD24V2023 can effectively inhibit the proliferation of breast cancer, liver cancer, pancreatic cancer, and gastric cancer cells, and can effectively inhibit the phosphorylation of STAT3 protein and activate AMPK phosphorylation.

[0028] In summary, the present invention provides a new use and potential molecular mechanism of 1-methyl-6-chromenoindole-2-carboxamide compounds and their derivatives in the treatment of tumors and metabolic diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 The result is that RD24V1001 can effectively inhibit STAT3 protein phosphorylation;

[0030] Figure 2 This is the result of RD24V1001 activating AMPK protein phosphorylation. DETAILED DESCRIPTION

[0031] In order to make the technical purpose, technical solution and beneficial effects of the present invention more clear, the technical solution of the present invention is further described below in conjunction with the accompanying drawings and specific embodiments.

[0032] In the method for synthesizing the compound of formula I of the present invention, various raw materials used in the reaction can be prepared by those skilled in the art according to prior knowledge, or can be prepared by methods known in the literature, or can be purchased commercially. The intermediates, raw materials, reagents, reaction conditions, etc. used in the above reaction schemes can be appropriately changed according to the prior knowledge of those skilled in the art.

[0033] In the present invention, unless otherwise specified: (i) the temperature is expressed in degrees Celsius (°C), and the operation is carried out at room temperature; more specifically, the room temperature refers to 20-30°C; (ii) the organic solvent is dried by a common drying method, and the solvent is evaporated using a rotary evaporator under reduced pressure, and the bath temperature is not higher than 50°C; the developing agent and the eluent are both in volume ratio; (iii) the reaction process is tracked by thin layer chromatography (TLC); (iv) the final product has a satisfactory proton nuclear magnetic resonance (1H-NMR).

[0034] Example 1: The synthesis of all compounds is as follows:

[0035] The specific synthesis method takes compound RD24V1001 as an example, and the structural formula is as follows:

[0036]

[0037] Its synthetic route is as follows:

[0038]

[0039] Step 1. (4-hydroxynaphthalen-1-yl)(4-(4-(2,2,2-trifluoroethoxy)benzyl)piperazin-1-yl)methanone (Compound 3)

[0040] Compound 1 (2.0 g, 10.63 mmol, 1.0 eq), compound 2 (2.92 g, 10.63 mmol, 1.0 eq), HBTU (4.85 g, 12.57 mmol, 1.2 eq) and DIEA (4.15 g, 31.38 mmol, 3.0 eq) were dissolved in 30 mL DMF, stirred at 25 °C for 3 hours, and the reaction was completed after TLC monitoring. The reaction solution was diluted with 200 mL ethyl acetate, washed three times with saturated brine (200 mL*3), the organic phase was dried and spin-dried, slurried with 15 mL ethyl acetate, and filtered to obtain 4.20 g of white solid compound 3, with a yield of 88.9%.

[0041] 1 H NMR (CDCl 3,300MHz)δ:8.27(d,J=8Hz,1H),7.80(d,J=8Hz,1H),7.55(m,2H),7.24(d,J=8Hz,1H),7. 20(d,J=8Hz,2H),6.88(d,J=8Hz,2H),6.79(d,J=8Hz,1H),4.34(m,3H),4.20-4.10(m,2H)

[0042] Step 2. (1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-2-yl)(4-(4-(2,2,2-trifluoroethoxy)benzyl)piperazin-1-yl)methanone (Compound 5)

[0043] Compound 3 (5 g, 9.80 mmol, 1.0 eq), compound 4 (4.98 g, 19.59 mmol, 2.0 eq), potassium acetate (2.88 g, 29.39 mmol, 3.0 eq), Pd(dppf)Cl 2 (350mg, 0.05eq) was dissolved in 50mL DMF and reacted at 100℃ for 12 hours. TLC monitoring showed that the raw material reaction was complete and new spots were generated. The reaction solution was diluted with 500mL ethyl acetate and washed three times with saturated brine (500mL*3). The organic phase was dried and spin-dried, passed through a column (DCM / MeOH=1 / 0~30 / 1 for elution), and the eluent containing compound 5 was collected and spin-dried to obtain 5g of white solid compound 5, with a yield of 91.56%.

[0044] 1 H NMR (CDCl 3 ,300MHz)δ:8.25(d,J=8Hz,1H),7.78(d,J=8Hz,1H),7.53(m,2H),7.22(d,J=8Hz,1H),7.18(d,J=8Hz,2H),6.86 (d,J=8Hz,1H),4.32(m,2H),4.20-4.13(m,3H),3.95-3.88(m,2H),2.85(s,3H),3.04-2.96(m,5H),1.2(m,12H).

[0045] Step 3.7-(1-methyl-2-(4-(4-(2,2,2-trifluoroethoxy)benzyl)piperazine-1-carbonyl)-1H-indol-6-yl)-4H-chromen-4-one(RD24V1001)

[0046] Compound 5 (1.20 g, 2.15 mmol, 1.0 eq), compound 6-1 (532.91 mg, 2.37 mmol, 1.1 eq), sodium carbonate (342.25 mg, 1.5 eq) and Pd(dppf)Cl 2 (75 mg, 0.05 eq) was dissolved in 20 mL DMSO and reacted at 100°C for 10 hours. TLC monitoring showed that the reaction of the raw material was complete and new spots were generated. The reaction solution was spin-dried, mixed with silica gel, and passed through a column (DCM / MeOH=1 / 0-30 / 1 elution). The eluent containing the product was collected and spin-dried to obtain RD24V1001, 120 mg, light yellow solid, 58.1%.

[0047] 1 H NMR (CDCl 3 ,300MHz)δ:8.25(d,J=8Hz,1H),7.87(d,J=8Hz,1H),7.78(d,J=8Hz,1H),7.53(m,2H),7.33((d,J=8Hz,2H),7.22(d,J=8Hz,2H),7.18(d ,J=8Hz,2H),6.86(d,J=8Hz,1H),6.35(d,J=8Hz,1H)4.32(m,2H),4.20-4.13(m,3H),3.95-3.88(m,2H),2.85(s,3H),3.04-2.96(m,5H).

[0048] Part of the intermediate 6 in this application was purchased from commercial sources, and part was obtained through the following synthetic route:

[0049]

[0050] The specific synthesis process is as follows:

[0051] a. Compound 7, compound 8 and LDA were dissolved in tetrahydrofuran, stirred at -78°C for complete reaction, the reaction solution was quenched with ammonium chloride solution, washed with saturated brine, dried, and subjected to column chromatography to obtain compound 9, wherein the molar ratio of compound 7, compound 8 and LDA was 1:1:2;

[0052] b. Compound 9 and Tf 2O was dissolved in dichloromethane, stirred at 0°C until the reaction was complete, the reaction solution was rotary dried, and column chromatography was performed to obtain compound 6a. The molar ratio of compound 9 to Tf2O was 1:1.5;

[0053] c. Compound 11, oxalyl chloride and pyridine were dissolved in DMF and stirred at room temperature until the reaction was complete. The reaction solution was diluted with ethyl acetate and washed with saturated brine. The organic phase was dried and subjected to column chromatography to obtain compound 12. The molar ratio of compound 11, oxalyl chloride and pyridine was 1:2:0.5;

[0054] d. Compound 12 was dissolved in DMF and stirred at 100°C until the reaction was complete. The reaction solution was diluted with ethyl acetate and washed with saturated brine. The organic phase was dried by spin drying and purified by column chromatography to obtain compound 6b.

[0055] Example 2, RD24V1001, RD24V1002, RD24V1003, RD24V1004, RD24V1005, RD24V1006, RD24V1007, RD24V1008, RD24V1009, RD24V1010, RD24V1011, RD24V1012, RD24V1013, RD24V1014, RD24V1015, RD24V1016, RD24V1017, RD24V1018, RD24V1019, RD24V1020, RD24V1021, RD24V1022, RD24V1023, RD24V1024, RD24V1001, RD24V1002 2. RD24V2003, RD24V2004, RD24V2005, RD24V2006, RD24V2007, RD24V2008, RD24V2009, RD24V2010, RD24V2011, RD24V2012, RD24V2013, RD24V2014, RD24V2015, RD24V2016, RD24V2017, RD24V2018, RD24V2019, RD24V2020, RD24V2021, RD24V2022, RD24V2023 have an inhibitory effect on the proliferation of breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, diffuse large B-cell lymphoma and other cells

[0056] MDA-MB-468, HepG2, BxPC-3, SGC7901, H460, KYSE450, Hela, MM.1S, and OCI-LY3 cells in the logarithmic growth phase were collected and counted, and the cell suspension concentration was adjusted to 5×10 4 / mL, added to a 96-well cell culture plate, with a volume of 100 μL per well. Using DMSO as a solvent control, the compounds RD24V1001, RD24V1002, RD24V1003, RD24V1004, RD24V1005, RD24V1006, RD24V1007, RD24V1008, RD24V1009, RD24V1010, RD24V1011, RD24V1012 described in the present invention were added to a 96-well cell culture plate, with a volume of 100 μL per well. , RD24V1013, RD24V1014, RD24V1015, RD24V1016, RD24V1017, RD24V1018, RD24V1019 , RD24V1020, RD24V1021, RD24V1022, RD24V1023, RD24V1024, RD24V2001, RD24V2002, RD24V2003, RD24V2004, RD24V2005, RD24V2006, RD24V2007, RD24V2008, RD24V2009, RD24V2010, RD24V2011, RD24V2012, RD24V2013, RD24V2014, RD24V2015, RD24V2016, R D24V2017, RD24V2018, RD24V2019, RD24V2020, RD24V2021, RD24V2022, and RD24V2023 were diluted with DMSO and added to the culture wells, so that the final concentrations of the compounds in the system were 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 (μmol / L), respectively. After continuing to culture for 72 hours, 10 / 20 μL of CCK-8 solvent was added to each well, incubated at 37°C for 3 hours, and the OD value at an absorption wavelength of 450nm was measured by an enzyme reader. The results were recorded, and the cell growth curve was drawn with the dosage of the compound as the horizontal axis and the absorbance value as the vertical axis. The statistical results of the half inhibition rate (IC50 value) of the compound on tumor cells are shown in Table 1 below:

[0057] Table 1. CCK-8 detects RD24V1001, RD24V1002, RD24V1003, RD24V1004, RD24V1005, RD24V1 006, RD24V1007, RD24V1008, RD24V1009, RD24V1010, RD24V1011, RD24V1012, RD2 4V1013, RD24V1014, RD24V1015, RD24V1016, RD24V1017, RD24V1018, RD24V1019 , RD24V1020, RD24V1021, RD24V1022, RD24V1023, RD24V1024, RD24V2001, RD24V2 002, RD24V2003, RD24V2004, RD24V2005, RD24V2006, RD24V2007, RD24V2008, RD24V2009, RD24V2010, RD24V2011, RD24V2012, RD24V2013, RD24V2014, RD24V2015, RD24V2016, RD24V2017, RD24V2018, RD24V2019, RD24V2020, RD24V2021, RD24V2022, RD24V2023 have an inhibitory effect on the proliferation of breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, diffuse large B-cell lymphoma and other cells.

[0058]

[0059]

[0060]

[0061] The table shows: RD24V1001, RD24V1002, RD24V1003, RD24V1004, RD24V1005, RD24V1006, RD24V1007, RD24V1008, RD24V1009, RD24V1010, RD24V1011, RD24V1012, RD24V1013, RD24V1014, RD24V 1015, RD24V1016, RD24V1017, RD24V1018, RD24V1019, RD24V1020, RD24V1021, RD24V1022, RD24V1023, RD24V1024, RD24V2001, RD24V2002, RD24V2003, RD24V2004, RD24V2005, RD24V 2006, RD24V2007, RD24V2008, RD24V2009, RD24V2010, RD24V2011, RD24V2012, RD24V2013, RD24V2014, RD24V2015, RD24V2016, RD24V2017, RD24V2018, RD24V2019, RD24V2020, RD24V 2021, RD24V2022, and RD24V2023 have good proliferation inhibitory effects on breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, diffuse large B-cell lymphoma and other cells, especially in breast cancer, multiple myeloma, and diffuse large B-cell lymphoma cells. The tumor inhibitory activity is stronger. This application uses RD24V1001 as an example to conduct a preliminary study on the anti-tumor mechanism of this type of compound.

[0062] Example 3: Effect of RD24V1001 on STAT3 phosphorylation and AMPK phosphorylation in MDA-MB-468 cells

[0063] 1. Cell culture and drug addition: a. Take MDA-MB-468 cells in the logarithmic growth phase and adjust the density to 2×10 5 2 mL of cell suspension was inoculated into each well of a 6-well plate. Incubate at 37°C and 5% CO 2 Incubate overnight in an incubator, add different concentrations of RD24V1001 to a final concentration of 0, 3, 10, 30, 100 nM), and use DMSO as a negative control. c. After culturing for 24 hours, lyse the cells with RIPA lysis buffer and collect the protein.

[0064] 2. Cell collection and lysis: a. Discard the upper culture medium and wash the cells twice with pre-cooled PBS. Add 100 μL of pre-cooled RIPA cell lysis buffer (protease inhibitors and PMSF are added to the lysis buffer in a ratio of 1:100 and mixed well) to each well.

[0065] b. Lyse on ice for 3 minutes, scrape the cells with a cell scraper and collect them into a 1.5 mL EP tube; place on ice for 30 minutes and vortex every 6 minutes.

[0066] c. Centrifuge at 4°C, 12000 g for 10 min. d. Transfer the cell supernatant to a new EP tube.

[0067] d. Divide the cell supernatant into two parts: take 5 μL and add it to a 1.5 mL EP tube for BCA protein content measurement, then add 45 μL of 1× PBS and mix well for later use; take 80 μL of the remaining cell supernatant, add 20 μL of 5× SDS Loading Buffer, mix well, boil in boiling water for 10 min, centrifuge and load on the sample or store in a -20°C refrigerator.

[0068] e. Protein concentration determination steps:

[0069] (1) Preparation of BCA working solution: Calculate the total amount of mixed working solution of A and B required based on the number of standards and samples to be tested. Prepare the working solution at a volume ratio of 50:1 for BCA solids A and B, vortex and mix well for later use.

[0070] (2) 1× PBS diluted protein standard:

[0071]

[0072]

[0073] (3) Take 25 μL of each of the protein standard solution and the sample supernatant diluted with PBS (10-fold dilution) and add them to a new 96-well plate. Then add 200 μL of the pre-prepared BCA working solution and mix thoroughly. Be careful not to blow and create bubbles. Cover the 96-well plate tightly and react in a 37°C incubator for 30 minutes.

[0074] (4) Take out the 96-well plate and return it to room temperature for 3-5 minutes. Measure the absorbance value of A562 on an ELISA reader and copy the obtained value to an Excel spreadsheet. Make a standard curve and calculate the protein content of 1 μL of each sample for protein loading.

[0075] 3. SDS-PAGE: (1) Fix the gel plate and prepare 10% SDS-PAGE separation gel.

[0076] Prepare separation gel according to the following table: 10 mL

[0077] Deionized water 4.0mL 30%(m / v)Acrylamide 3.3mL 1.5M Tris-HCl (PH 8.8) buffer 2.5mL 10%(m / v)SDS 0.1mL 10%(m / v)APS 0.1mL TEMED 4μL Total 10mL

[0078] (2) Add the mixed separation gel to two gel plates, add to the position 1.0 cm from the top, fill the gel plates with anhydrous ethanol, and let it stand for 30 to 45 minutes. (3) After the separation gel is solidified, pour out the remaining anhydrous ethanol and absorb the remaining anhydrous ethanol with filter paper. (4) Prepare 5 mL of 5% concentrated gel according to the table below

[0079]

[0080]

[0081] (5) Slowly add the prepared concentrated glue to the glue plate to avoid generating bubbles, insert a comb, and let it stand for 30 to 45 minutes.

[0082] (6) Take out the protein sample, heat it in a water bath at 100°C for 5 minutes, and centrifuge it at 10,000 rpm for 5 minutes. (7) Fix the gel plate to the electrophoresis tank, add SDS-PAGE electrophoresis buffer, pull out the comb, and add the processed protein samples to the sample tank in order, 50 μg of protein per well. (8) Perform electrophoresis at 80V for 40 minutes. (9) Change the voltage to 120V for about 1.5 hours until bromophenol blue runs out of the colloid;

[0083] IV. Western-blot: (1) Rinse the SDS-PAGE gel after electrophoresis in TBST buffer once, and soak the protein gel in transfer buffer. (2) Soak a layer of cotton pad in membrane transfer buffer, clamp it to the transfer instrument with tweezers, and place it in the order of blackboard, cotton pad, filter paper, protein gel, PVDF membrane, filter paper, cotton pad and white board, clamp it, and put it into the transfer instrument. If there are bubbles between each layer, use a glass tube to gently roll them out. (3) Turn on the transfer instrument and transfer at 300mA constant current for 80min. (4) Put the membrane in TBST buffer and rinse 3 times, 8min each time. (5) Block with 20mL of 5% BSA-TBST blocking solution at room temperature for 2h. (6) Add primary antibody and incubate overnight at 4℃60rpm. (7) Wash the membrane three times with TBST at room temperature, shaking at 60rpm, 10min each time. (8) Add secondary antibody and incubate at room temperature for 1h. (9) Wash the membrane three times with TBST at room temperature, shaking at 60 rpm, for 10 min each time. (10) Take 1 mL each of chemiluminescent substrate solution A and solution B, and color develop at room temperature for 2 min. (11) Use filter paper to absorb the liquid on the membrane and expose it to light.

[0084] 5. Reagent preparation:

[0085] (1) 10% SDS: Weigh 1 g of high-purity (electrophoresis grade) SDS into a 10 mL centrifuge tube, add about 8 mL of deionized water, heat to dissolve, dilute to 10 mL, and store at room temperature.

[0086] (2) 10% ammonium persulfate (AP): weigh 1 g of ammonium persulfate, add about 10 mL of deionized water, stir to dissolve, and store at 4°C.

[0087] (3) 5× electrophoresis buffer: weigh 15.1 g of Tris, 94 g of Glycine, and 5.0 g of SDS into a beaker, add 1 L of double distilled water to dissolve, store at room temperature, and dilute 5 times before use.

[0088] (4) Transfer buffer: Weigh 5.8 g of Tris, 11.6 g of glycine, and 0.75 g of SDS into a beaker, add 700 mL of double distilled water, dissolve and adjust the volume to 800 mL, and finally add 200 mL of methanol.

[0089] (5) 1.5 mol / L Tris-HCl, 100 mL: Dissolve 18.15 g Tris in 80 mL water and adjust the pH to 8.8 with 4 N HCl. Make up to 100 mL.

[0090] (6) 0.5 mol / L Tris-HCl, 1000 mL: Weigh 60.5 g of Tris base, add water to 850 mL, add concentrated hydrochloric acid and stir until completely dissolved, then adjust the pH to 6.8 and add water to 1 L.

[0091] (7) TBS buffer: Weigh 8.8 g of NaCl and dissolve it in 800 mL of distilled water. Add 10 mL of 1 mol / L TrisHCl (pH 7.5) to make up to 1 L and store at room temperature.

[0092] (8) TBST buffer: Add 500 μL of 20% Tween 20 to 1 L of TBS buffer to make the final concentration of Tween 20 0.1%. Prepare it before use.

[0093] (9) Blocking solution, antibody diluent: Add 5% skim milk powder or BSA to TBST buffer and prepare it before use.

[0094] like Figure 1 The results showed that 30nM and 100nM RD24V1001 treatment could effectively downregulate the expression levels of p-STAT3(Y705), p-STAT3(S727) and STAT3's downstream target proteins C-MYC and CyclinD1.

[0095] like Figure 2The results showed that 10nM and 30nM RD24V1001 treatment could effectively activate the phosphorylation of AMPK and the phosphorylation level of AMPK's downstream target protein ACC.

[0096] In summary, the results show that RD24V1001, RD24V1002, RD24V1003, RD24V1004, RD24V1005, RD24V1006, RD24V1007, RD24V1008, RD24V1009, RD24V1010, RD24V1011, RD24V1012, RD24V1013, RD24V1014, RD24V1015, RD24V1016, R D24V1017, RD24V1018, RD24V1019, RD24V1020, RD24V1021, RD24V1022, RD24V1023, RD24V1024, RD24V 2001, RD24V2002, RD24V2003, RD24V2004, RD24V2005, RD24V2006, RD24V2007, RD24V2008, RD24V2009, RD24V2010, RD24V2011, RD24V2012, RD24V2013, RD24V2014, RD24V2015, RD24V2016, RD24V2017, RD24V2018, RD24V2019, RD24V2020, RD24V2021, RD24V2022, RD24V2023 can significantly inhibit breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer It can inhibit the proliferation of cells such as cancer, multiple myeloma, diffuse large B-cell lymphoma, and can effectively downregulate the expression levels of p-STAT3 (Y705), p-STAT3 (S727) and STAT3's downstream target proteins C-MYC and CyclinD1. Therefore, this type of drug has good anti-cancer effect and development potential; in addition, this type of compound can also activate AMPK phosphorylation, so this type of compound also has great application potential in metabolic diseases (such as weight loss, non-alcoholic fatty liver disease).

[0097] According to the general approach of drug development (conventional anti-tumor in vitro screening first, then targeted research), the compounds of the present invention can be applied to cancer treatment drugs related to abnormal cell proliferation, and can be prepared as anti-tumor drugs and metabolic disease drugs by mixing with human-acceptable salts or with pharmaceutical carriers.

[0098] Finally, it should be noted that the above embodiments are only used to illustrate but not limit the technical solutions of the present invention, and any equivalent substitutions of the present invention and any modifications or partial substitutions that do not depart from the spirit and scope of the present invention should be included in the scope of protection of the claims of the present invention.

Claims

1. A 1-methyl-6-chromenoindole-2-carboxamide compound, It is characterized in that The structural formula is shown in general formula I: Among them, R 1 , R 2 Selected from H, -OH, -NO 2 、-NO 2 , —OCH 3 、F、Cl、Br、 2. The 1-methyl-6-chromenoindole-2-carboxamide compound according to claim 1, It is characterized in that Specifically, the compound has the following structure:

3. A biologically acceptable salt formed by the 1-methyl-6-chromenone indole-2-carboxamide compound according to claim 1 or 2 and at least one of acetic acid, dihydrofolic acid, benzoic acid, citric acid, sorbic acid, propionic acid, oxalic acid, fumaric acid, maleic acid, hydrochloric acid, malic acid, phosphoric acid, diphosphoric acid, hydrobromic acid, nitric acid, sulfurous acid, sulfuric acid, vanillic acid, tartaric acid, succinic acid, ascorbic acid, boric acid, lactic acid, p-toluenesulfonic acid, salicylic acid and ethylenediaminetetraacetic acid.

4. The method for preparing the 1-methyl-6-chromenone indole-2-carboxamide compound according to claim 1, It is characterized in that The synthetic route is as follows: The specific synthesis steps are as follows: (1) Compound 1, Compound 2, HBTU and DIEA were dissolved in DMF, and after the reaction was completed by stirring at 20-30° C., the reaction solution was diluted with ethyl acetate and washed with saturated brine. The organic phase was spin-dried, slurried with ethyl acetate, and filtered to obtain Compound 3; (2) Compound 3, compound 4, Pd(dppf)Cl 2 and potassium acetate were dissolved in DMF, stirred at 90-120°C until the reaction was complete, the reaction solution was diluted with ethyl acetate, washed with saturated brine, the organic phase was dried by spin drying, and column chromatography was performed to obtain compound 5; (3) Compound 5, Compound 6, Pd(dppf)Cl 2 and sodium carbonate are dissolved in DMSO, stirred at 90-120° C. until the reaction is complete, the reaction solution is diluted with ethyl acetate and washed with saturated brine, the organic phase is spin-dried and subjected to column chromatography to obtain the compound of formula I.

5. The method for preparing 1-methyl-6-chromenone indole-2-carboxamide compounds according to claim 4, It is characterized in that In step (1), the molar ratio of compound 1, compound 2, HBTU and DIEA is 1:1:(1-1.5):3; step (2) In the solution, compound 3, compound 4, potassium acetate and Pd(dppf)Cl 2 The molar ratio is 1:2:3:0.05; in step (3), compound 5, compound 6, sodium carbonate and Pd(dppf)Cl 2 The molar ratio is 1:(1~1.5):(1~1.5):0.

05.

6. Use of the 1-methyl-6-chromenoindole-2-carboxamide compound or a biologically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of a STAT3 protein phosphorylation inhibitor.

7. Use of the 1-methyl-6-chromenoindole-2-carboxamide compound or a biologically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of an anti-tumor drug, Features: The anti-tumor drug refers to a drug for treating breast cancer, liver cancer, pancreatic cancer, gastric cancer, lung cancer, esophageal cancer, cervical cancer, multiple myeloma, and diffuse large B-cell lymphoma.

8. Use of the 1-methyl-6-chromenoindole-2-carboxamide compound or a biologically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of a drug for activating AMPK.

9. Use of the 1-methyl-6-chromenoindole-2-carboxamide compound or a biologically acceptable salt thereof according to any one of claims 1 to 3 in the preparation of metabolic drugs, Features: The medicine is a medicine for treating diabetes and obesity.

Citation Information

Patent Citations

  • Isoindolinyl-piperazinyl urea compound as well as preparation method and application thereof

    CN116554158A

  • Diaryl acetylene compound as well as preparation method and application thereof

    CN116715657A

  • Piperazine indole amide compound as well as preparation method and application thereof

    CN116768864A

  • Piperazine naphthyl formamide compound as well as preparation method and application thereof

    CN118063410A